Dr. Sateesh Belemkar

Qualification              : M. Pharm., Ph.D.

Specialization             : Pharmacology

E mail                         : Sateesh.b@nmims.edu

Phone                         : 022-42332000 (Extn-2017)

Experience                 : 30 years

Belemkar studied B Pharm (1994, Gulbarga University), M Pharm (1997, Karnatak University) and Ph.D (2010, NMIMS University) from reputed Institutions. He is having vast experience in teaching subjects of Anatomy & Physiology, Pathophysiology and Pharmacology & Toxicology to UG & PG. He is having expertise in handling Industrial toxicity projects and associated with pharmaceutical industries as consultant.He has conducted clinical study of antidiabetic formulations as a part of Ph D studies & registered with CTRI. He is a CCSEA nominated member and actively involved in IAEC activities.

Interest areas:  

• Inflammation
• Diabetes
• Toxicology

Research

• Publications – Total number (International- 50, National-23)

• Book Chapters- Total number (3)
• Presentations- Total number (International- 6 National-9)
• Government-funded projects – Total number (Data should match with MIS data)
  • Completed (Title of the project, funding agency, amount in Rs. (i.e. Rs.31.00 lakh)
  • Ongoing (Title of the project, funding agency, amount in Rs.)
• Industry projects
• ICMR project: Study of the effect of SARS-CoV-2, Zika virus and Epstein-Barr virus infection for progress of Fragile X Syndrome and development of therapeutic modalities for management (2024), Amount: 4442940, Duration: 3 years (Ongoing)

• RGSTC Project : Sysnthesis and formulation of novel polymer based drug eluting stents coating for extended release (2025), Amount: 34 lakhs, Duration: 3 years (Ongoing)

• Pharmacokinetic study of vitamin formulation, Septlyst Life Sciences Mumbai, Project cost 6 lakhs. (2025) (Ongoing)
• Size reduction & Formulation study of vitamin Preparation, Septalyst Life Sciences, Mumbai, Project cost 6.5 lakhs (Ongoing, 2024). (Ongoing)
• Evaluation of Novel Formulation on Sprague Dawle Rats, Amaterasu, Mumbai. Project cost 0.65 Lakhs. (Completed 2024).
• Ophthalmic study of NCE, Ajanta Pharma, Mumbai. Project fund 0.75 Lakhs (Completed 2022).
• In-Vitro antioxidant activity and in-vivo studies on a pharmaceutical composition for Diabetic Nephropathy funded by Septalyst Lifesciences Pvt Ltd, Mumbai. Project cost Rs. 4.5 lakhs (Completed, 2020-2021)
• Toxicity study of 6 new drug formulations of Lupin Ltd, Mumbai, project cost Rs.3 lakhs. (Completed, 2010-2012)
• Toxicity study of 10 new drug formulations of Research & Regulatory Services, Thane, project cost Rs.2.5 lakhs. (Completed, 2013-2015)
• Consultancy services for 10 toxicity studies of Research & Regulatory Services, Mumbai, worth Rs. 1 lakh carried out. (Completed, 2013-2015)
• Toxicity study of 11 new drug formulations of Ajanta Pharma Ltd Mumbai, project fund Rs. 30 lakhs. (completed 2015-2018)

Conferences/Workshops/Seminars attended- 19

Academic activities

• He has guided 36 M.Pharm. students for their research projects. 
• He has guided 3PhD students successfully and 4 candidates are registered under his supervision. 

Professional Memberships

Life Member of APTI, IPA and IPS.

Recent Publications

1. Pandya, K., Roul, K., Tripathi, A., Belemkar, S., Sinha, A., Erol, M., & Kumar, D. (2025). Alzheimer’s disease: A review of molecular mechanisms and therapeutic implications by targeting sirtuins, caspases, and GSK-3. ACS Chemical Neuroscience, 16(12), 2178–2195. https://doi.org/10.1021/acschemneuro.5c00207 (IF-4.2)
2. Maru, S., & Belemkar, S. (2025). Acute and subacute oral toxicity study of a herbal formulation containing Asparagus racemosus, Tinospora cordifolia, and Trigonella foenum-graecum in mice. Journal of Toxicology. https://doi.org/10.1155/jt/8221552 (IF-3.0)
3. Maru, S., & Belemkar, S. (2025). Comparative study of lactogenic effect and milk nutritional density of oral galactagogue in female rabbit. Current Protein & Peptide Science, 26(2), 125–138. https://doi.org/10.2174/0113892037300581240830052536 (IF-2.5)
4. Maru, S., & Belemkar, S. (2025). Nurturing wellness: Development and evaluation of a novel herbal formulation with immunomodulatory activity. Pharmacognosy Magazine. https://doi.org/10.1177/09731296241311345 (IF-0.9)
5. Bhirud, D., Bhattacharya, S., Raval, H. V., Sangave, P., Gupta, G., Paraskar, G., Jha, M., Sharma, S., Belemkar, S., Kumar, D., Maheshwari, R., & Sharma, M. (2025). Chitosan nanoparticles of imatinib mesylate coated with TPGS for the treatment of colon cancer: In-vivo and in-vitro studies. Carbohydrate Polymers, 348. https://doi.org/10.1016/j.carbpol.2024.122935 (IF-12.5)
6. Raka, S., Belemkar, S., & Bhattacharya, S. (2024). Hybrid nanoparticles for cancer theranostics: A critical review on design, synthesis, and multifunctional capabilities. Current Medicinal Chemistry. (IF-3.5)
7. Raval, H. V., Bhattacharya, S., Bhirud, D., & Chidambar, P. (2025). Fabrication of lactoferrin-chitosan-etoposide nanoparticles with melatonin via carbodiimide coupling: In-vitro and in-vivo evaluation for colon cancer. Journal of Controlled Release, 377, 820–841. https://doi.org/10.1016/j.jconrel.2024.11.077 (IF-11.5)
8. Bhattacharya, S., Belemkar, S., & Prajapati, B. G. (2024). The application of graphene oxide nanoarchitectures in the treatment of cancer: Phototherapy, immunotherapy, and the development of vaccines. Current Medicinal Chemistry, 31(27), 4320–4339. https://doi.org/10.2174/0109298673288750240117115141 (IF-3.5)
9. Bhadane, P. K., Roul, K. A., & Belemkar, S. (2024). Immunotherapeutic approaches for Alzheimer’s disease: Exploring active and passive vaccine progress. Brain Research. https://doi.org/10.1016/j.brainres.2024.149018 (IF-2.6)
10. Bhattacharya, S., Sangave, P. C., Belemkar, S., & Anjum, M. M. (2024). pH-sensitive nanoparticles of epigallocatechin-3-gallate in enhanced colorectal cancer therapy. Nanomedicine, 19(6), 459–481. https://doi.org/10.2217/nnm-2023-0342 (IF-1.89)